AFP
news@thelocal.ch
@thelocalswitzer
17 April 2018
A health worker and a mother try to get down the fever of a boy with malaria in the Democratic Republic of Congo in 2017. 238 more words
Tags » Novartis
Switzerland's Novartis to inject $100 million into malaria drug research
Deficits, Gene Therapy, S&P Earnings Growth - Things I Learned This Week - April 15, 2018
Article: Deficits Won’t Matter – Until They Do, Barron’s
- We are entering unchartered territory with the budget deficits in the U.S.
- For the past three months, retail sales have fallen. 277 more words
European fundraising in good shape
BACKGROUND
Begin the weekend post in Berlin, with the German Biotech Startup Report. Labiotech.eu has team up with Euronext and Bio Deutschland to publish last Wednesday 2017 German startup ecosystem summary. 840 more words
Novartis anuncia buenos resultados de Entresto® en estudio PARADIGM-HF.
Un análisis post-hoc del estudio PARADIGM-HF, que fue publicado en la revista JAMA Cardiology, anunció que la combinación de sacubitril y valsartán (Entresto®, de Novartis) resultó superior a enalapril para brindar mejoría en cuanto a las limitaciones que sufren los pacientes con insuficiencia cardíaca para realizar actividades físicas y sociales.1,2 Como reconoció el doctor Scott Solomon, profesor de medicina del Brigham and Women’s Hospital, de la Escuela de Medicina de Harvard, los pacientes con insuficiencia cardíaca crónica suelen experimentar una reducción importante de su calidad de vida, incluso al compararlos con quienes padecen otras enfermedades crónicas. 211 more words
Why Did Novartis Spend $9 Billion On Gene Therapy? CEO Says: 'A Journey To Focus On Data And Digital'
(Source: www.forbes.com)
Johnny Wolf
This morning, Novartis announced it would buy gene therapy pioneer AveXis for $8.7 billion, giving the Swiss drug giant several treatments for rare diseases that work by inserting new DNA into patients’ cells. 374 more words
Novartis to expand gene therapy pipeline with acquisition of AveXis for $8.7 billion
Novartis plans to acquire the neurological gene therapy firm AveXis for $8.7 billion. The purchase will bolster the Swiss giant’s standing as a big pharma leader in the emerging gene therapy field. 54 more words
